期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
TRIP13:A promising cancer immunotherapy target
1
作者 Shengnan Jing Liya Zhao +2 位作者 Liwen Zhao Yong‐Jing Gao Tianzhen He 《Cancer Innovation》 2024年第6期1-10,共10页
The tumor microenvironment(TME)facilitates tumor development through intricate intercellular signaling,thereby supporting tumor growth and suppressing the immune response.Thyroid hormone receptor interactor 13(TRIP13)... The tumor microenvironment(TME)facilitates tumor development through intricate intercellular signaling,thereby supporting tumor growth and suppressing the immune response.Thyroid hormone receptor interactor 13(TRIP13),an AAA+ATPase,modulates the conformation of client macromolecules,consequently influencing cellular signaling pathways.TRIP13 has been implicated in processes such as proliferation,invasion,migration,and metastasis during tumor progression.Recent studies have revealed that TRIP13 also plays a role in immune response suppression within the TME.Thus,inhibiting these functions of TRIP13 could potentially enhance immune responses and improve the efficacy of immune checkpoint inhibition.This review summarizes the recent research progress of TRIP13 and discusses the potential of targeting TRIP13 to improve immune‐based therapies for patients with cancer. 展开更多
关键词 immune responses immune‐based therapies thyroid hormone receptor interactor 13 tumor microenvironment
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部